Dermal matrix remodeling after nonablative laser therapy - 21/08/11
, John J. Voorhees, MD, Ted Hamilton, MS, Craig Hammerberg, PhD, Sewon Kang, MD, Timothy M. Johnson, MD, Darius J. Karimipour, MD, Gary Fisher, PhD
Reprint requests: Jeffrey S. Orringer, MD, University of Michigan Health System, 1910 Taubman Center, 1500 E Medical Center Dr, Ann Arbor, MI 48109-0314.Ann Arbor, Michigan
Abstract |
Objective |
Nonablative laser therapy is widely practiced for cutaneous rejuvenation. We sought to quantify dermal molecular changes after exposure of photodamaged skin to nonablative laser energy.
Methods |
Nonablative laser therapy of forearm skin using either a 585-nm wavelength pulsed dye laser or a 1320-nm wavelength neodymium:yttrium-aluminum-garnet laser was performed. Serial biopsy specimens were obtained at baseline and various times after treatment.
Results |
Statistically significant increases in type I procollagen messenger RNA expression occurred after exposure of photodamaged skin to each laser. Induction was 47% (P < .05) and 84% (P < .05) above baseline levels 1 week after laser therapy among those treated with the pulsed dye and neodymium:yttrium-aluminum-garnet lasers, respectively. Substantial induction of type III procollagen, various matrix metalloproteinases, and primary cytokines was also demonstrated. Responses with respect to all molecules studied were highly variable.
Limitations |
This study addresses molecular changes after a single laser exposure whereas clinically, serial treatments are often provided.
Conclusions |
Nonablative laser therapy may result in quantifiable alterations in molecules associated with remodeling of the dermal matrix, although responses vary greatly among patients.
Il testo completo di questo articolo è disponibile in PDF.Mappa
| Supported in part by the University of Michigan Department of Dermatology Laser Research Fund. ICN Pharmaceuticals Inc donated the NLite and CoolTouch lasers. During the course of this study, ICN Pharmaceuticals Inc divested itself of its Photonics subsidiary, which was responsible for these devices. However, we were permitted to retain the lasers to complete our study. Of note, at the time of this divestiture, ICN Pharmaceuticals Inc had no knowledge of the outcomes of this study. The project was also supported, in part, by a Dermatology Foundation Clinical Career Development Award in Dermatologic Surgery (Dr Orringer). Conflicts of interest: None identified. |
Vol 53 - N° 5
P. 775-782 - novembre 2005 Ritorno al numero
Articolo precedente
- Long-term treatment of photoaged human skin with topical retinoic acid improves epidermal cell atypia and thickens the collagen band in papillary dermis
- Soyun Cho, Lori Lowe, Ted A. Hamilton, Gary J. Fisher, John J. Voorhees, Sewon Kang
- Skin cancer in organ transplant recipients: Effect of pretransplant end-organ disease
- Clark C. Otley, Wida S. Cherikh, Stuart J. Salasche, Maureen A. McBride, Leslie J. Christenson, H. Myron Kauffman
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?